ArticleCancer science2025
Discovery-Replication Strategy Identifies Serum Metabolite Biomarkers for Colorectal Cancer in a Chinese Cohort.
Article in Cancer science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Multi Omics Integration in Colorectal Cancer: From Molecular Insights to Precision Oncology.Cancers · 2026Review
- N-phenethylacetamide, diaminopimelic acid, and Gly-Val as high-performance serum biomarkers for diagnosing untreated Graves' disease: an LC-MS-based metabolomics study.Frontiers in endocrinology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Early diagnosis of colorectal cancer (CRC) is difficult to achieve. The use of serum metabolites may be a noninvasive diagnostic method for CRC; however, few studies have examined this method in China. This study aimed to analyze serum metabolite alterations and their diagnostic value for CRC in a Chinese cohort. Serum metabolomics analysis was performed via liquid chromatography-mass spectrometry in a discovery cohort of 20 CRC patients and 20 healthy controls. The diagnostic value of differential serum metabolites was verified by LASSO regression and receiver operating characteristic (ROC) curve analysis. Furthermore, an independent validation cohort of 80 CRC patients and 80 controls was established. A total of 1299 serum metabolites, including 311 differentially abundant metabolites, were detected in the discovery cohort. LASSO regression revealed that 8 metabolites could distinguish CRC patients from controls: among which 2-hydroxyhexadecanoic acid, 3-hydroxypentadecanoic acid, 5(S)-HETE, glutamine pyruvate, lactic acid, and lysoPC (0:0/16:0) were elevated in CRC patients, whereas DG (8:0/10:0/0:0) and cis-muconic acid were decreased. Each of the elevated metabolites had a high diagnostic value for CRC, with an AUC exceeding 0.80. The panel of 8 metabolites was superior for diagnosing CRC, with an AUC of 0.968, a sensitivity of 0.95, and a specificity of 1.00. The validation cohort replicated the results of the discovery cohort and further confirmed that the metabolite panel was valuable for the early diagnosis and assessment of lymph node metastasis. In conclusion, our study revealed that serum metabolites could be used for CRC detection.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.